FENNEC PHARMACEUTICALS INC
FENCNASDAQ🏆 #3067 by market capEarnings Nov 5US Equity
$10.92▲ $0.07 (+0.65%)
Market closed · at closeTrack FENC
Get earnings, price moves & breaking news on Telegram
24h▲ 0.7%
7d▲ 8.4%
14d▲ 9.1%
30d▲ 2.7%
ytd▲ 41.8%
1y▲ 31.1%
🏦Market Cap
$383M
Small Cap
📈Revenue Growth (YoY)
33.8%
High Growth
📊Gross Margin
93.7%
High
💵FCF Margin
6.6%
Moderate
⚖️P/S Ratio
6.4x
Fair
Otter Score
72
Strong
Trading Snapshot
- Day Range
- $10.80 – $11.14
- 52-Week Range
- $5.65 – $13.25
- Volume (shares)
- 11,032
- Avg Volume (shares)
- —
- Shares Outstanding
- 35.1M
- Next Earnings
- 2026-11-05
Fundamentals Snapshot
- Annual Revenue
- $45M
- Last Q Revenue
- $18M
- P/E Ratio
- —
- P/S Ratio
- 6.4x
- EPS (TTM)
- $-0.12
- Dividend Yield
- —
- Dilution (1yr)
- +13.5%
FENNEC PHARMACEUTICALS INC
FENCFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$45M▼ −6.1% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
91.6%▼ −1.9% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$6M▼ −356.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$12M▼ −146.2% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
31.2M▲ +13.5% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$37M▲ +$29M YoY
StockOtter · stockotter.spaceAbout FENNEC PHARMACEUTICALS INC
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading investigational drug in clinical development is PEDMARK, a specialized formulation of sodium thiosulfate. This treatment is designed to shield young cancer patients from hearing damage (ototoxicity) that can be induced by platinum-based chemotherapy. The company, which was founded in 1996, previously operated under the name Adherex Technologies Inc. before officially rebranding as Fennec Pharmaceuticals Inc. in September 2014. Its corporate headquarters are situated in Research Triangle Park, North Carolina.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Strong
72/100
Analyst Ratings
ⓘConsensus
Buy
12 analysts
Strong Buy3
Buy8
Hold1
Sell0
Strong Sell0
Ratings as of Oct 2026
Latest News & Updates
News unavailable.